CLOV Quote, Financials, Valuation and Earnings

Centene has a net margin of -6.56% compared to Clover Health Investments's net margin of 0.69%. Clover Health Investments's return on equity of -13.55% beat Centene's return on equity of 12.3%.

Clover Health Investments has a consensus price target of $4.75, signalling upside risk potential of 29.43%. On the other hand Centene has an analysts' consensus of $79.45 which suggests that it could grow by 27.34%. Given that Clover Health Investments has higher upside potential than Centene, analysts believe Clover Health Investments is more attractive than Centene.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Centene has a beta of 0.529, suggesting its less volatile than the S&P 500 by 47.066%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centene offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Centene pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are smaller than Centene quarterly revenues of $40.8B. Clover Health Investments's net income of -$22.1M is lower than Centene's net income of $283M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Centene's PE ratio is 10.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.37x versus 0.20x for Centene. Usually stocks with elevated PS ratios are considered overvalued.

NeueHealth has a net margin of -6.56% compared to Clover Health Investments's net margin of -1.17%. Clover Health Investments's return on equity of -13.55% beat NeueHealth's return on equity of -3241.93%.

Clover Health Investments has a consensus price target of $4.75, signalling upside risk potential of 29.43%. On the other hand NeueHealth has an analysts' consensus of $7.00 which suggests that it could grow by 7.2%. Given that Clover Health Investments has higher upside potential than NeueHealth, analysts believe Clover Health Investments is more attractive than NeueHealth.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NeueHealth has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeueHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. NeueHealth pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are larger than NeueHealth quarterly revenues of $232.6M. Clover Health Investments's net income of -$22.1M is lower than NeueHealth's net income of -$2.7M. Notably, Clover Health Investments's price-to-earnings ratio is -- while NeueHealth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.37x versus 0.06x for NeueHealth. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of -6.56% compared to Clover Health Investments's net margin of -6.42%. Clover Health Investments's return on equity of -13.55% beat Oscar Health's return on equity of 2.46%.

Clover Health Investments has a consensus price target of $4.75, signalling upside risk potential of 29.43%. On the other hand Oscar Health has an analysts' consensus of $19.36 which suggests that it could grow by 58.02%. Given that Oscar Health has higher upside potential than Clover Health Investments, analysts believe Oscar Health is more attractive than Clover Health Investments.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are smaller than Oscar Health quarterly revenues of $2.4B. Clover Health Investments's net income of -$22.1M is higher than Oscar Health's net income of -$153.5M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Oscar Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.37x versus 0.36x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -6.56% compared to Clover Health Investments's net margin of 3.53%. Clover Health Investments's return on equity of -13.55% beat Progyny's return on equity of 11.14%.

Clover Health Investments has a consensus price target of $4.75, signalling upside risk potential of 29.43%. On the other hand Progyny has an analysts' consensus of $26.75 which suggests that it could grow by 20.17%. Given that Clover Health Investments has higher upside potential than Progyny, analysts believe Clover Health Investments is more attractive than Progyny.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Progyny has a beta of 1.328, suggesting its more volatile than the S&P 500 by 32.843%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are larger than Progyny quarterly revenues of $298.4M. Clover Health Investments's net income of -$22.1M is lower than Progyny's net income of $10.5M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Progyny's PE ratio is 39.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.37x versus 1.85x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.